Bio-waiver of Sapro­pterin dihydrochloride powder for oral solution [Dissolution / BCS / IVIVC]

posted by AB661 – India, 2019-11-22 18:49 (1672 d 22:49 ago) – Posting: # 20861
Views: 4,784

Dear All,

We are developing Sapropterin dihydrochloride powder for oral solution,

We are going to file BCS based Bio-waiver approach using solubility, dissolution & composition similarity.

But for permeability study there is no literature support for human absolute bioavailability study or in-vitro permeability study of Sapropterin dihydrochloride. Whether USFDA accept our proposal without permeability study data ?

With regards
AB


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,665 registered users;
27 visitors (0 registered, 27 guests [including 5 identified bots]).
Forum time: 18:39 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5